1st U-PGx Personalized Medicine Day
The "1st U-PGx Personalized Medicine Day" event will be held on December 1, 2016, in the Paraninfo auditorium of the Health Sciences Technology Park in Granada. The meeting is organized by the Golden Helix Foundation, ibs.GRANADA, the FIBAO Foundation, the Granada Hospital Complex, and the University of Granada. It is the first in a series of events to be organized in different European countries as part of the outreach activities of the U-PGx project, funded by the European Commission under the H2020 program (GA No. 668353).
The invited speakers at the event are illustrious personalities in the field of personalized medicine in Europe. On this occasion, the event will focus on genomics-guided treatment in cardiovascular diseases.
Health professionals may attend this international event: doctors, hospital pharmacists, Medicine and Pharmacy students, researchers, laboratory technicians and people interested in pharmacogenomics.
In principle, the capacity is limited to 150 people.
Organizing committee
Cristina Lucia Davila Fajardo (Granada, ES)
George P. Patrinos (Patras, GR)
Miquel Tarron (Madrid, ES)
Opening speech
Sir Munir Pirmohamed (Liverpool, UK)
Invited speakers
Bassam R. Ali (Al-Ain, UAE)
Norma Anwar (London, UK)
Antonio Carcas Sansuán (Madrid, ES)
Vera Deneer (The Hague, NL)
Juan Jimenez Jaimez (Granada, ES)
Henk-Jan Guchelaar (Leiden, NL)
Theodora Katsila (Patras, GR)
Mikko Niemi (Helsinki, FI)
George P. Patrinos (Patras, GR)
Jesse Swen (Leiden, NL)
Registration is free (financed by the European project) and must be done through the page:
About the U-PGx project
The U-PGx (Ubiquitous Pharmacogenomics) project aims to address the main challenges and obstacles for the implementation of pharmacogenomics (PGx) in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, the U-PGx project will investigate whether an approach in which the patient receives treatment guided by a pharmacogenomic test that includes a panel of important pharmacogenomic markers, results in fewer adverse drug reactions, better results in health for patients and is cost-effective compared to routine clinical practice. With this new approach, the genetic information related to the response to different drugs will be included in the patient's medical history, so that when the drug is prescribed by the doctor or dispensed by the hospital pharmacist, the recommendation of the hospital can be obtained. personalized medication for each patient. This new model of personalized medicine through preventive PGx tests will be carried out on a large scale in seven European hospitals and healthcare centers (Netherlands, Spain, United Kingdom, Italy, Austria, Greece, Slovenia)
This project has received funding from the European Union's Horizon 2020 Research and Innovation Program under Grant Agreement No 668353.
